How to optimize current treatment of genotype 2 hepatitis C virus infection
Article first published online: 23 DEC 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Special Issue: Proceedings of the 7th Paris Hepatitis Conference International Conference of the Management of Patients with Viral Hepatitis, 13–14 January 2014, Paris, France. Guest Editors: Patrick Marcellin and Tarik Asselah. The publication of this supplement was supported by an unrestricted educational grant from Gilead, Janssen Therapeutics, Janssen, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Merck, AbbVie, Novartis, Idenix and Alios.
Volume 34, Issue Supplement s1, pages 13–17, February 2014
How to Cite
Marciano, S. and Gadano, A. C. (2014), How to optimize current treatment of genotype 2 hepatitis C virus infection. Liver International, 34: 13–17. doi: 10.1111/liv.12399
- Issue published online: 23 DEC 2013
- Article first published online: 23 DEC 2013
- 6European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–64.
- 19Final results of ENABLE 1, a phase 3, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis c virus-related Chronic liver disease associated with thrombocytopenia. Hepatology 2011; 54: 360A–1445A., , , et al.
- 22Treatment with sofosbuvir + ribavirin for 12 weeks achieves svr12 of 78% in GT 2/3 interferon-ineligible,-intolerant, or -unwilling patients: results of the phase 3 POSITRON trial. J Hepatol 2013; 58: S25–44., , , et al.
- 23Daclatasvir combined with peginterferon alfa-2a And ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013; 58: S25–44., , , et al.